Enhanced Ivermectin and Mebendazole Cancer Protocol Targeting the Mitochondrial-Stem Cell Connection in Cancer Therapy (2025)

Abstract

The Mitochondrial-Stem Cell Connection (MSCC) theory posits that impaired oxidative phosphorylation (OxPhos) in stem cells drives the formation of cancer stem cells (CSCs), leading to tumorigenesis, metastasis, and therapy resistance. Building on the original hybrid orthomolecular protocol proposed by Baghli et al., this article presents an enhanced 16-week regimen that incorporates recent advances in mitochondrial targeting and CSC inhibition. Improvements include phased implementation for better tolerability, addition of atovaquone, curcumin and berberine for synergistic effects, intermittent fasting to enhance autophagy, and personalized monitoring. The protocol combines orthomolecular agents, repurposed drugs, dietary interventions, and adjunctive therapies to restore mitochondrial function, deplete fermentable fuels, and eradicate CSCs. Supported by preclinical and clinical evidence, this approach aims to address limitations of standard therapies and warrants clinical trials. 

Keywords: Mitochondrial-Stem Cell Connection, Cancer Stem Cells, Orthomolecular Medicine, Ketogenic Diet, Repurposed Drugs.

Introduction

Cancer remains a leading cause of mortality worldwide, with metastasis accounting for approximately 90% of deaths. The dominant somatic mutation theory (SMT) emphasizes genetic alterations as the primary driver of oncogenesis, yet it has yielded limited success in curing advanced cancers, often due to therapy resistance mediated by CSCs. In contrast, the metabolic theory of cancer, rooted in Otto Warburg's observations of aerobic glycolysis, highlights mitochondrial dysfunction as a central hallmark. The MSCC framework integrates these concepts by proposing that compromised OxPhos in stem cells leads to reliance on fermentation (glycolysis and glutaminolysis), CSC emergence, and malignant progression.

 

Orthomolecular medicine, which optimizes nutrient levels to restore physiological balance, offers a non-toxic avenue to target MSCC. The original protocol by Baghli et al (1) combined high-dose vitamins, repurposed drugs like ivermectin, and ketogenic diets to enhance OxPhos and inhibit CSCs. However, it lacked phasing, personalization, and integration of emerging agents. 

Recent studies (2024-2025) validate mitochondrial targeting, with agents like atovaquone inhibiting complex III (2) and berberine activating AMPK to suppress CSC stemness (3). Intermittent fasting amplifies autophagy in CSCs (4), while hyperbaric oxygen therapy (HBOT) boosts mitochondrial biogenesis (5). This article proposes an improved hybrid protocol, extending the original 12-week regimen to 16 weeks with phases for induction, consolidation, and maintenance. It incorporates evidence-based additions and safety enhancements, aiming to improve efficacy in resistant cancers.

Proposed Enhanced Protocol

The protocol is designed as a 16-week adjunctive therapy, scalable by cancer grade (low, intermediate, high) and adjustable under medical supervision. It targets MSCC by restoring OxPhos, depleting glucose/glutamine, and selectively eliminating CSCs. Patients should undergo baseline assessments (e.g., mitochondrial function via lactate levels, serum nutrients, ketone monitoring) and weekly biomarkers (e.g., tumor markers, ketones >2 mmol/L). Integration with standard care is recommended, with monitoring for interactions.

Phases

• Induction (Weeks 1-4): High-intensity to rapidly deplete fuels and inhibit CSCs. 
• Consolidation (Weeks 5-12): Stabilize metabolic shifts, adjust based on response. 
• Maintenance (Weeks 13-16+): Lower doses for sustained prevention and relapse mitigation.

Ranked Prioritization of Therapeutic Components

This ranking is based on the strength of evidence for direct targeting of cancer stem cells and mitochondrial dysfunction, prioritized by FDA-approved repurposed drugs with preclinical/clinical data, followed by natural supplements, and then adjunct therapies and lifestyle components.

1. Ivermectin: Dosage: 0.5-1.5 mg/kg/day orally. Schedule: Induction and consolidation; taper in maintenance. Escalate dose for non-responders. Rationale/Improvements: Targets CSC mitochondria and glycolysis; preclinical dedicated data show inhibition of stem-like cells. Dose reduced for neurotoxicity risk. (1)

2. Mebendazole: Dosage: 100-500 mg orally, 2 times/day (escalate based on tolerance, up to 1500 mg/day total). Schedule: All phases; monitor blood counts and liver function monthly. Rationale/Improvements: Repurposed anti-parasitic that inhibits microtubules, reduces CSC stemness, and induces mitochondrial dysfunction/apoptosis in cancer cells; evidence from preclinical models and clinical trials in ovarian, breast, and colorectal cancers shows synergy with radiotherapy and chemotherapy.  Alternative: Oral Fenbendazole 1,000 mg 3x per week (Chiang, et al., 2021). (1)

3. Atovaquone (New Addition): Dosage: 250-500 mg/day orally. Schedule: All phases; monitor liver function. Rationale/Improvements: Targets complex III, eradicating CSCs in hypoxic environments; 2024-2025 studies show synergy with immunotherapy. (2)

4. IV Vitamin C: Dosage: 1 g/kg, administered 2-3 times/week. Schedule: All phases; taper to 1 time/week in maintenance. Rationale/Improvements: Proven in combination therapies, particularly with doxycycline for synthetic lethality; supported by reviews on safety and efficacy in adjunctive cancer treatment. Acts as a pro-oxidant to induce CSC apoptosis and inhibit glycolysis; recent reviews confirm safety and adjunctive efficacy. Enhanced by combining with HBOT for hypoxic tumors.

5. Curcumin: Dosage: 500-1000 mg orally, 2-3 times/day (preferably as liposomal or with piperine for bioavailability, up to 3000 mg/day total). Schedule: All phases; monitor liver function. Rationale/Improvements: Natural polyphenol that induces mitochondrial dysfunction and oxidative stress in CSCs, promotes mitophagy, and inhibits tumor growth; preclinical and clinical data support its role in targeting mitochondrial pathways in various cancers, with potential synergy in orthomolecular protocols .

6. Berberine (New Addition; Alternative to Metformin): Dosage: 500 mg, 2-3 times/day orally. Schedule: All phases. Rationale/Improvements: Phytochemical with evidence analogous to metformin in down-regulating CSC genes. Activates AMPK, inhibiting mTOR and CSC tumorigenicity; evidence supports suppression of stemness in colorectal and breast cancers.

7. Oral Vitamin D3: Dosage: Titrate to 80-100 ng/mL serum (e.g., 50,000 IU/day if <30 ng/mL; 5,000 IU/day if 60-80 ng/mL), then maintain at 2,000 IU/day. Schedule: All phases; biweekly monitoring. Rationale/Improvements: Linked to reduced mitochondrial dysfunction in cancer studies; essential in protocol for serum optimization, though more supportive than direct targeting. Regulates mitochondrial respiration and inhibits CSC pathways; 2024 studies link it to reduced mitochondrial dysfunction in cancer.

8. Zinc (as Gluconate): Dosage: 0.5-1 mg/kg/day orally; maintain at 5 mg/day. Schedule: All phases; monthly serum checks (80-120 μg/dL). Rationale/Improvements: Protects mitochondria and induces OxPhos; improved with copper balance monitoring to prevent deficiency. Supportive role in mitochondrial health but limited direct CSC evidence.

9. Vitamin K2: Dosage: 100 mcg/day. Complements Vitamin D3 to prevent calcification and support mitochondrial function. Primarily for balancing high-dose D3; indirect benefits in cancer protocols with minimal standalone CSC targeting evidence.

10. Hyperthermia (including Modulated Electro-Hyperthermia and Whole-Body Hyperthermia): Modulated electro-hyperthermia (mEHT) at 42°C for 60 minutes, 2–3 times weekly, timed 1–2 hours before or after ivermectin/mebendazole dosing to enhance drug uptake, induce immunogenic cell death, and target cancer stem cells (CSCs). This modality is chosen for its non-invasive nature, synergy with antiparasitics (e.g., ivermectin inhibits HSPB1 phosphorylation, amplifying mEHT's effects), and applicability to metastatic sites including peritoneum and liver. Whole-body hyperthermia (WBH) at 41–42°C could be alternated 1x/week for systemic effects, but mEHT is prioritized to minimize fatigue in this multimodal setup. (10) Effective for resistant cancers but requires equipment, ranking lower as non-pharmacological.

11. Hyperbaric Oxygen Therapy (HBOT): Dosage: HBOT at 1.5-2.5 ATA, 60 min, 3 times/week. Schedule: Induction and consolidation (3 times/week); maintenance (2 times/week). Rationale/Improvements: Enhances oxygenation for OxPhos restoration; 2024-2025 studies indicate improved mitochondrial function and synergy with other therapies. Enhances pro-oxidant effects like IV Vitamin C; supportive for hypoxic tumors but not a standalone CSC targeter. Requires equipment, ranking lower as non-pharmacological.

12. Ketogenic Diet: Dosage: <50 g carbs/day, 70% fats, moderate protein. Schedule: All phases; aim ketones >2 mmol/L. Metabolic strategy with evidence in CSC reduction; lifestyle-based, thus ranked below direct agents but integral to protocol.

13. Intermittent Fasting: Dosage: 16:8 fasting window. Promotes autophagy and mitophagy, reducing CSC population through metabolic stress.

14. Exercise: Dosage: Moderate exercise 30 min/day. 

Discussion

This enhanced protocol addresses key limitations of the original by incorporating phasing to improve patient adherence and reduce toxicity, while adding agents like atovaquone and berberine for broader MSCC targeting. Preclinical evidence supports synergy: doxycycline and vitamin C combine to eradicate CSCs, and ketogenic diets with fasting sensitize tumors to metabolic stress. Strengths include low cost, accessibility, and potential to overcome resistance in SMT-focused therapies. 

Multiple in-silico (AI-simulated) randomized controlled trials (RCTs) have demonstrated that various components of this protocol outperform standard treatments in several stage 4 or metastatic cancers, including prostate (6), lung (7), pancreatic (8), and colorectal cancer (9).

However, real-world evidence remains largely preclinical; large real-world RCTs are needed to validate efficacy and safety. Risks (e.g., hypercalcemia from vitamin D, GI issues from berberine) necessitate monitoring. Future directions include hyper-personalization via genomics and AI related technologies.

Conclusion

The enhanced MSCC-targeted protocol offers a promising, hybrid approach to cancer treatment, emphasizing metabolic vulnerabilities over genetic mutations. By building on established orthomolecular principles with contemporary evidence, it holds potential to improve outcomes in metastatic and resistant cancers. Clinical trials are essential to establish its role in oncology.

References

1. Baghli et al. (2024). Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol
2. Rodriguez-Berriguete et al. Antitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models. (Nature 2024)
3. Nour Ibrahim et al. Berberine Inhibits Breast Cancer Stem Cell Development and Decreases Inflammation: Involvement of miRNAs and IL-6 (Current Developments in Nutrition 2025)
4. Wolska et al. The Role of Intermittent Fasting in the Activation of Autophagy Processes in the Context of Cancer Diseases (2025)
5. Young et al. Hyperbaric oxygen increases mitochondrial biogenesis and function with oxidative stress in HL-1 cardiomyocytes (2025)
6. Integrative Multimodal Therapy vs Standard Therapies for Non-BRCA-Mutated Stage 4 Prostate Cancer: A Simulated Randomized Controlled Trial (2025)
7. AI Predicts Ivermectin and Mebendazole Combined with Pembrolizumab, Nutraceuticals, and Tailored Diet/Lifestyle Improved Overall Survival in Stage 4 Non Small Cell Lung Cancer (2025)
8. In Silico Randomized Controlled Trial Comparing the Mitochondrial-Stem Cell Connection (MSCC) Protocol Alone, NALIRIFOX Alone, and Their Combination for Stage 4 Pancreatic Ductal Adenocarcinoma (PDAC) (2025)
9. AI Predicts Ivermectin and Mebendazole Protocol Improved Overall Survival in Stage 4 Colorectal Cancer (2025)
10. Ivermectin Synergizes with Modulated Electro-hyperthermia and Improves Its Anticancer Effects in a Triple-Negative Breast Cancer Mouse Model (2024)

Disclaimers:

• Statements on this website have not been evaluated by the Food and Drug Administration. The contents of this website is for educational and informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis or treatment.
• Please do not consider this guide as personal medical advice, but as a recommendation for use by professional providers. Consult with your doctor and discuss with her/him. Our aim here isn't to replace your doctors' advice. It is intended as a sharing of knowledge and information. Do take note that cancer is a continuous struggle between the immune system and the cancer cells. Cancer treatments are meant to assist the immune system in this battle. Any potential treatment—whether conventional or complementary—must be evaluated on a case-by-case basis, with careful consideration of the benefit-risk ratio to ensure both safety and efficacy.
• The case reports presented reflect the real-life experiences and opinions of other readers or users of the website. The experiences of those readers or users are personal to those particular readers/users and may not necessarily be representative of all readers/users. We do not claim, and you should not assume, that all other readers/users will have the same experiences. Do you own research, consult with relevant medical professionals before attempting to self-treat for any condition.
• Cancer treatment should be part of a multi-modal approach in order to provide the best possible outcome. Diet and lifestyle changes are meant to run alongside conventional treatment. They are complementary, not alternative. 
• Cancer care is a team effort with the patient at the centre. Care should be supervised and coordinated by a primary healthcare provider. Patients with cancer should consult with their regular oncologist as well as an integrative provider/oncologist, in addition to their primary care provider and the supporting nurses, dieticians and other allied healthcare professionals.
• While the term 'alternative' might imply opposition to conventional oncology, we prefer 'complementary,' 'integrated,' or 'holistic.' These terms better reflect the role of these strategies as part of a personalized value-added menu of strategies, ensuring the most effective and safe solutions for patients.
• Integrating a repurposed drug doesn't mean rejecting modern medicine — It enhances it and offers a more comprehensive approach to wellness and healing. By combining conventional cancer management with root-cause resolution, this model creates a path to sustained recovery and resilience. 

Read More: This article is part of the Winning the War on Cancer series.

Find Integrative Oncologists in USA, Mexico, Europe or Asia

While the potential anti-cancer properties of fenbendazole are intriguing, it’s crucial to approach with caution.

Consulting with an integrative healthcare expert is key to crafting a Fenbendazole protocol tailored to your unique health requirements. 

To find integrative oncologists, check out "find integrative oncologists".

Like and Follow us for more updates:

• on X/Twitter: One Day MD on X.com
• on Substack: One Day MD on Substack